Drugs / Cenicriviroc
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03376841 | Jun → Nov 2017 | liver disease, severe congenital | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT02684799 | Jan → Apr 2016 | — | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02342067 | Dec 2014 → Mar 2015 | — | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02120547 | Mar → Jul 2014 | liver disorder | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01827540 | Mar → May 2013 | HIV infectious disease | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01092104 | Feb → Nov 2009 | HIV infectious disease | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 210 trials · 5 missed | ||||||
| Phase 2 | NCT05630885 | May 2023 → Jun 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT04334915 | Nov 2022 → Aug 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 2 | NCT04488081 | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | Missed primary |
| Phase 2 | NCT03517540 | Sep 2018 → Sep 2020 | metabolic dysfunction-associated steatohepatitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03059446 | Feb 2017 → Jan 2021 | NAFLD1, cirrhosis of liver, metabolic dysfunction-associated steatohepatitis | Tobira Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02653625 | Mar 2016 → Aug 2017 | primary sclerosing cholangitis | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02330549 | Jul 2015 → Aug 2016 | fatty liver disease, prediabetes syndrome, type 2 diabetes mellitus | Tobira Therapeutics, Inc. | Completed | Missed primary |
| Phase 2 | NCT02217475 | Sep 2014 → Jun 2016 | metabolic dysfunction-associated steatohepatitis | Tobira Therapeutics, Inc. | Completed | Missed primary |
| Phase 2 | NCT02128828 | Apr 2014 → Jun 2016 | AIDS dementia complex, HIV infectious disease | University of Hawaii | Completed | No outcome recorded |
| Phase 2 | NCT01338883 | Jun 2011 → Dec 2012 | HIV infectious disease | Tobira Therapeutics, Inc. | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03028740 | Apr 2017 → Jan 2021 | metabolic dysfunction-associated steatohepatitis | Tobira Therapeutics, Inc. | Terminated | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04500418 Comparator | Aug 2020 → Jul 2021 | COVID-19 | Charite University, Berlin, Germany | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04593940 Comparator | Oct 2020 → Jan 2022 | COVID-19 | Daniel Benjamin | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cenicriviroc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02342067 ↗ |
| Known as | Cenicriviroc mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110727 ↗ |
| Known as | Cenicriviroc Mesylate | “The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission...” NCT05630885 ↗1“Arm A: Cenicriviroc Mesylate (CVC)” NCT04334915 ↗ |
| Known as | CVC | “A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate...” NCT02342067 ↗8“This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC).” NCT02653625 ↗ “Cenicriviroc (CVC), a dual-CCR2/CCR5 antagonist, has potent anti-inflammatory and antifibrotic activity in animal models” PMID 26944023 ↗ Mar 2016 “Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.” NCT02330549 ↗ “Cenicriviroc (CVC), an oral, once-daily C-C chemokine receptor types 5 and 2 antagonist” PMID 26636929 ↗ Mar 2016 “Arm A: Cenicriviroc Mesylate (CVC)” NCT04334915 ↗ “Cenicriviroc (CVC) 150 mg” NCT03059446 ↗ “Cenicriviroc (CVC)” NCT04500418 ↗ |
| Known as | TAK-652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110727 ↗ |
| Known as | TBR 652 | “A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral...” NCT01092104 ↗ |
| Action | Inhibit | “TBR-652, a CCR5/CCR2 antagonist” PMID 21317794 ↗ Jun 2011 |
| Modality | Small molecule | — CHEMBL2110727 ↗ |
| Route | Oral | “TBR-652 monotherapy given once daily orally for 10 days” PMID 21486960 ↗ Apr 2011 |
| Target | CCR2 | “TBR-652, a CCR5/CCR2 antagonist” PMID 21317794 ↗ Jun 2011 |
| Target | CCR5 | “TBR-652, a CCR5/CCR2 antagonist” PMID 21317794 ↗ Jun 2011 |